The industry is becoming extremely data-driven, and the integration of heterogeneous data in a dynamic environment is becoming central to success.
At BioLizard, we provide innovative solutions to diverse biological questions, including data management, data architecture, data visualisation, data analytics, and data interpretation. All of our services are tailored to your needs, to help you make the most of your biomedical data.
BioLizard is proud to have received the Best Poster Award at the European Society for Spatial Biology (ESSB) conference, recognising our work on benchmarking cell segmentation methods for single-cell spatial transcriptomics.
Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their operations and unlock greater value from their data.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
